Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Net Income

Bottom-line profit after all expenses, interest, and taxes.

Genelux CorporationNASDAQ: GNLX

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income remains negative

Q1 FY2026 net income was -$7.13M, compared with -$7.49M a year earlier. Trailing-twelve-month net income was -$31.78M.

Context

  • Net income amounted to 401812.5% of revenue in FY2025, up 28450.0 pp from a year earlier.
  • Net income grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 4 analysts of -$31.04M (+3.4%) for the fiscal year ending Dec 2026, a step up from the -7.6% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.13M+22.9% QoQ
Last fiscal yearDec 2025
-$32.15M-7.6% YoY
LTMMar 2026
-$31.78M-7.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.9%-18.6%-23.5 pp
1 year-7.6%+3.4%+11.1 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the income statement

Latest · FY2025
(32.15M) USD
Year-over-year change
-7.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -7.7% is the 5th highest of 10, against a peer median of -11.2%.
  • Net income amounts to 397225.0% of revenue for GNLX, versus a peer median of 7139.7%.
GNLX Competitors
Net Income for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026-$27.37M USD+52.6%——
GNLXGenelux CorporationLTM Mar 2026-$31.78M USD-7.7%—397225.0%
MREOMereo BioPharma Group plcLTM Mar 2026-$35.7M USD+24.2%—7139.7%
CADLCandel Therapeutics, Inc.LTM Mar 2026-$54.42M USD-37.5%——
DRTSAlpha Tau Medical Ltd.LTM Mar 2026-$56.88M USD-75.2%——
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026-$58.44M USD-17.3%——
ACIUAC Immune S.A.LTM Mar 2026-CHF 66.22M CHF-27.1%—1788.8%
CLLSCellectis S.A.LTM Mar 2026-$67.29M USD-11.2%—98.8%
SLNSilence Therapeutics plcLTM Mar 2026-$85.17M USD——9243.0%
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026-$87.5M USD+19.9%——
LYELLyell Immunopharma, Inc.LTM Mar 2026-$246.41M USD+26.3%—794858.1%
Peer median (excluding GNLX) —-11.2%—7139.7%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue011.07M170K8K8K
Cost of Revenue895K968K1.02M903K574K
Gross Profit(895K)10.1M(848K)(895K)(566K)
Gross Margin—91.3%-498.8%-11187.5%-7075.0%
Research & Development6.32M9.08M12.77M19M19.85M
Selling, General & Admin8.29M5M11.57M12.71M13.37M
Operating Expenses13.72M13.11M23.32M30.8M32.65M
Depreciation & Amortization895K968K1.02M903K574K
EBITDA(13.67M)(1.73M)(26.46M)(28.97M)(31.57M)
EBITDA Margin—-15.6%-15562.9%-362075.0%-394637.5%
Operating Income(14.61M)(3.01M)(24.17M)(31.7M)(33.21M)
Operating Margin—-27.2%-14214.7%-396200.0%-415175.0%
Interest Income00244K1.46M1.07M
Interest Expense1.82M1.41M3.97M00
Other Income / Expenses(1.77M)(1.09M)(4.13M)1.83M1.07M
Income Before Tax(16.38M)(4.11M)(28.3M)(29.87M)(32.15M)
Pre-Tax Margin—-37.1%-16645.3%-373362.5%-401812.5%
Income Tax Expense01.1M000
Net Income(17.8M)(5.21M)(28.3M)(29.87M)(32.15M)
Net Margin—-47.0%-16645.3%-373362.5%-401812.5%
EPS (Basic)(0.69)(0.21)(1.16)(0.95)(0.86)
EPS (Diluted)(0.69)(0.21)(1.16)(0.95)(0.86)
Weighted Avg Shares23.62M24.55M24.43M31.45M37.18M
Weighted Avg Shares (Diluted)23.62M24.55M24.43M31.45M37.18M

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.